Prentice Capital Management, LP Immunome Inc. Transaction History

Prentice Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.7 - $7.91 $1.5 Million - $2.53 Million	-319,773 Reduced 74.04%	112,131 $886,000
Q1 2023 May 15, 2023	SELL	$3.26 - $5.69 $215,945 - $376,911	-66,241 Reduced 13.3%	431,904 $2.16 Million
Q4 2022 Feb 14, 2023	SELL	$2.21 - $5.0 $649,023 - $1.47 Million	-293,676 Reduced 37.09%	498,145 $1.1 Million
Q2 2022 Aug 15, 2022	SELL	$2.24 - $5.79 $1,120 - $2,895	-500 Reduced 0.06%	791,821 $2.54 Million
Q1 2022 May 16, 2022	SELL	$3.88 - $13.99 $55,096 - $198,658	-14,200 Reduced 1.76%	792,321 $4.5 Million
Q4 2021 Feb 14, 2022	BUY	$12.96 - $23.44 $3.75 Million - $6.78 Million	289,341 Added 55.95%	806,521 $10.5 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $32.33 $3.02 Million - $5.99 Million	185,185 Added 55.78%	517,180 $8.95 Million
Q1 2021 May 17, 2021	SELL	$9.56 - $43.24 $809,464 - $3.66 Million	-84,672 Reduced 20.32%	331,995 $11.2 Million
Q4 2020 Feb 12, 2021	BUY	$9.46 - $14.16 $3.94 Million - $5.9 Million	416,667 New	416,667 $4.03 Million

127

46.4M

322K

1.91M

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $132M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

Get notified when there are updates to the investment portfolio of Prentice Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prentice Capital Management, LP with notifications on news.